Document:

EX-10.4.2

 Exhibit 10.4.2 

FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT 

THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 28, 2014, is entered
into by and among AMEDICA CORPORATION, a Delaware corporation (“Borrower”), US SPINE, INC., a Delaware corporation (“Guarantor”), the Lenders (as defined below) and GENERAL ELECTRIC CAPITAL
CORPORATION, a Delaware corporation (“GECC”), in its capacity as administrative and collateral agent (together with its successors and assigns in such capacity, the “Agent”) for the Lenders (as defined below).

 W I T N E S S E T H: 

WHEREAS, Borrower, Guarantor, Agent, and the lenders signatory thereto from time to time (each a “Lender” and,
collectively, the “Lenders”), are parties to that certain Loan and Security Agreement, dated as of December 17, 2012 (as has been and may be amended, restated, supplemented, replaced, and otherwise modified from time to time,
the “Loan Agreement”; capitalized terms used herein have the meanings given to them in the Loan Agreement except as otherwise expressly defined herein), pursuant to which Lenders and Agent have agreed to provide to Borrower certain
loans in accordance with the terms and conditions thereof; and 
 WHEREAS, Borrower, Lenders, and Agent desire to amend certain
provisions of the Loan Agreement as provided herein; 
 NOW, THEREFORE, in consideration of the premises, the covenants and
agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Agent hereby agree as follows: 

1 AMENDMENTS TO LOAN AGREEMENT. Subject to the terms and conditions of this Amendment, including, without limitation, Section 4 of this
Amendment, the Loan Agreement is hereby amended as follows: 
 (a) Liquidity Covenant. Section 7.10(b) of the Loan Agreement
shall not be tested for the period from November 1, 2013 until February 28, 2014. Such limitation shall cease to be effective as of March 1, 2014 and thereafter, during which Borrower shall be required to comply with
Section 7.10(b) of the Loan Agreement. 
 2 RESERVE. On the date hereof, Agent shall establish a Reserve pursuant to
Section 2.1(b) of the Loan Agreement, in the amount of $500,000 (the “Fifth Amendment Reserve”), which shall remain in place until removed by Agent in its Permitted Discretion. For the avoidance of doubt, the Fifth
Amendment Reserve is in addition to (i) the $500,000 Reserve established pursuant to that certain Third Amendment and Waiver to Loan and Security Agreement dated as of August 15, 2013, by and among Borrower, Guarantor, Agent and Lenders,
and (ii) the $500,000 Reserve established pursuant to that certain Fourth Amendment to Loan and Security Agreement dated as of December 23, 2013, by and among Borrower, Guarantor, Agent and Lenders (“Fourth Amendment”).

 3 AMENDMENT FEE. Borrower shall pay to Agent, for the benefit of Lenders in accordance with their
Pro Rata Shares, an amendment fee in an amount equal to $200,000 on March 31, 2014 if Borrower has not terminated the Revolving Loan Commitments and paid all Obligations in full on or prior to March 31, 2014 (“Fifth Amendment
Fee”). The Fifth Amendment Fee is in addition to the fees required in the Fourth Amendment and the other Loan Documents. 
 4 CONDITIONS TO
EFFECTIVENESS. This Amendment shall become effective upon satisfaction of each of the following conditions: 
 (a) No Default or
Event of Default shall have occurred and be continuing; 
 (b) Agent shall have received one or more counterparts of this Amendment, duly
executed, completed and delivered by Agent, each Lender and each Loan Party; and 
 (c) Agent shall have received all other documents and
instruments as Agent or any Lender may reasonably deem necessary or appropriate to effectuate the intent and purpose of this Amendment. 
 5
REAFFIRMATION OF LOAN DOCUMENTS. By executing and delivering this Amendment, each Loan Party hereby (i) reaffirms, ratifies and confirms its Obligations under the Loan Agreement and the other Loan Documents, (ii) agrees that
this Amendment shall be a “Loan Document” under the Loan Agreement and (iii) hereby expressly agrees that the Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in
connection herewith. 
 6 REAFFIRMATION OF GRANT OF SECURITY INTEREST IN COLLATERAL. Each Loan Party hereby expressly reaffirms, ratifies and
confirms its obligations under the Loan Agreement, including its grant, pledge and hypothecation to the Agent for the benefit of the Agent and each Lender, of the lien on and security interest in, all of its right, title and interest in, all of the
Collateral. 
 7 NO OTHER CONSENTS OR AMENDMENTS. Except for the amendments set forth in this Amendment, the Loan Agreement and the other Loan
Documents shall remain unchanged and in full force and effect. Nothing in this Amendment is intended, or shall be construed, to constitute a novation or an accord and satisfaction of any Loan Party’s Obligations under or in connection with the
Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent’s security interest in, (on behalf of itself and Lenders) security titles to or other liens on any Collateral for the Obligations.

 8 REPRESENTATIONS AND WARRANTIES; LIENS; NO DEFAULT, NO CONFLICT. Each Loan Party hereby represents, warrants and covenants with and to the
Agent and Lenders as follows: (i) all of the representations and warranties set forth in the Loan Documents continue to be true and correct as of the date hereof, except to the extent such representations and warranties by their terms expressly
relate only to a prior date (in which case such representations and warranties shall be true and correct as of such prior date); (ii) there are no Defaults or Events of Default that have not been waived or cured; (iii) Agent has and shall
continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted 

  
 2 

 
Liens, on and security interests in the Collateral and all other collateral heretofore granted by each Loan Party to Agent, for the benefit of the Agent and each Lender, pursuant to the Loan
Documents or otherwise granted to or held by Agent, for the benefit of the Agent and each Lender, (iv) the agreements and obligations of Loan Parties contained in the Loan Documents and in this Amendment constitute the legal, valid and binding
obligations of the Loan Parties party thereto, enforceable against each such Loan Party in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general
application affecting the enforcement of creditors’ rights or by the application of general principles of equity, and (v) the execution, delivery and performance of this Amendment by each Loan Party will not violate any law, rule,
regulation or order or contractual obligation or organizational document of such Loan Party and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues. 

9 ADVICE OF COUNSEL. Each of the parties represents to each other party hereto that it has discussed this Amendment with its counsel. 

10 SEVERABILITY OF PROVISIONS. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable in any
applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

11 FURTHER ASSURANCES. Each Loan Party agrees that at any time and from time to time, at the expense of each Loan Party, it will promptly
execute and deliver all further instruments and documents, and take all further action, that may be necessary or that Agent or Lenders may reasonably request, in connection with this Amendment, or to enable them to exercise and enforce their rights
and remedies under this Amendment, the Loan Agreement and the other Loan Documents. 
 12 COSTS AND EXPENSES. Each Loan Party shall be
responsible for the payment of all fees, costs and expenses incurred by Agent and Lenders in connection with the preparation and negotiation of this Amendment, including, without limitation, any and all fees and expenses of Agent’s and
Lenders’ counsel. 
 13 REFERENCE TO THE EFFECT ON THE LOAN AGREEMENT. 

(a) Upon the effectiveness of this Amendment, each reference in the Loan Agreement to “this Agreement,” “hereunder,”
“hereof,” “herein” or words of similar import shall mean and be a reference to the Loan Agreement as modified by this Amendment. 

(b) The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided in this Amendment, operate as a waiver
of any right, power or remedy of Agent or any Lender, nor constitute a waiver of any provision of the Loan Agreement or any other documents, instruments and agreements executed or delivered in connection with the Loan Agreement. 

14 ACKNOWLEDGMENT OF EACH LOAN PARTY. Each Loan Party hereby acknowledges and agrees that: (i) it has no defense, offset or counterclaim
with respect to the 

  
 3 

 
payment of any sum owed to Agent or Lenders, or with respect to the performance or observance of any warranty or covenant contained in the Loan Documents; and (ii) Agent and Lenders have
performed all obligations and duties owed to each Loan Party through the date hereof. 
 15 GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE WITHOUT REGARD TO THE PRINCIPLES THEREOF REGARDING CONFLICTS OF LAWS. 

16 HEADINGS. Section headings in this Amendment are included for convenience of reference only and shall not constitute a part of this Amendment
for any other purpose. 
 17 ENTIRE AGREEMENT. The Loan Agreement and the other Loan Documents as and when amended through this Amendment
embody the entire agreement between the parties hereto relating to the subject matter thereof and supersede all prior agreements, representations and understandings, if any, relating to the subject matter thereof. 

18 COUNTERPARTS. This Amendment may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which when
taken together shall constitute one and the same instrument. Delivery of an executed signature page of this Amendment by facsimile transmission, portable document format (.pdf), or other electronic transmission shall be as effective as delivery of a
manually executed counterpart hereof. 
 [Remainder of page intentionally blank; signature pages follow.] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Fifth Amendment to Loan and
Security Agreement to be duly executed and delivered as of the day and year specified at the beginning hereof. 
  

			
	 BORROWER:
  

AMEDICA CORPORATION

		
	By:	 	/s/ Eric K. Olson
	 Name:
 Title:
	 	 Eric K. Olson
 President and
CEO

  

			
	 GUARANTOR:
  

US SPINE, INC.

		
	By:	 	/s/ Eric K. Olson
	 Name:
 Title:
	 	 Eric K. Olson
 President and
CEO

  

			
	 AGENT AND LENDER:
  

GENERAL ELECTRIC CAPITAL CORPORATION, as Agent and Lender

		
	By:	 	/s/ Scott R. Towers
	 Name:
 Title:
	 	 Scott R. Towers
 Duly Authorized
Signatory

  

			
	 LENDER:
  

ZIONS FIRST NATIONAL BANK

		
	By:	 	/s/ Thomas C. Etzel
	 Name:
 Title:
	 	 Thomas C. Etzel
 Senior Vice
PresidentEX-10.7

 CONFIDENTIAL TREATMENT REQUESTED 

Exhibit 10.7 
 JOINT
DEVELOPMENT AND LICENSE AGREEMENT 
 This Joint Development Agreement (the “Agreement”) entered into as of the 8th day of February, 2010 (the “Effective Date”) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah
84119 (“Amedica”) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 O’Connell Way #10, East Taunton, MA 02718 (“OSI”). Amedica and OSI are each referred to herein as a
“Party” and collectively as “Parties”. 
 WHEREAS, Amedica develops, manufacturers, markets, and sells implantable
medical devices and related products and instrumentation for the treatment of spinal and joint diseases, disorders, and injuries (the “Amedica Products”); 

WHEREAS, certain of the Amedica Products are manufactured utilizing a material known as Silicon Nitride (“SiN”) which material in
known to have particularly unique properties with respect to strength, wear, and bone ingrowth; 
 WHEREAS, OSI manufacturers, markets, and
sells implantable medical devices, including total hip and knee systems and related instrumentation; 
 WHEREAS, OSI is interested in
utilizing certain of Amedica’s technology, including without limitation SiN, to develop new implantable orthopedic products as more fully described herein, which products would also use existing OSI technology; 

WHEREAS, Amedica is interested in collaborating with OSI as more fully set out herein to develop products utilizing Amedica’s SiN
technology, which products will be owned and distributed as provided in this Agreement; and 
 WHEREAS, contemporaneously with the
negotiation and execution of this Agreement, the Parties are negotiating the terms and conditions of a distribution agreement the subject of which is ex-US distribution of products utilizing OSI’s Highly Cross-Linked Polyethylene and
Amedica’s SiN femoral head technology (the “Distribution Agreement”). 
 NOW THEREFORE, for the consideration contained
herein, the receipt and sufficiency of which is acknowledged by both Parties, Amedica and OSI agree to jointly develop the Products as that term is defined herein and to carry out various other activities related to the Products, as more fully set
out herein, pursuant to the following terms and conditions: 
 ARTICLE I 

JOINT DEVELOPMENT PRODUCTS AND RESPONSIBILITIES 

1.1 Products. The following products are to be jointly developed by Amedica and OSI pursuant to the terms and conditions
contained herein (collectively, “the Products”): 
  

	 	1.1.1	SiN [***] utilizing Amedica’s [***] and [***] and [***] (the “SiN Hip System”); 

  

	 	1.1.2	SiN [***], which shall include all [***]including without limitation a [***], utilizing [***] (collectively, the “Total Knee Components”): 

 

	 	1.1.3	SiN [***] (the “SiN Spacer”); and 

  

	 	1.14	A unicondylar knee system utilizing Amedica’s SiN femoral component and/or tibial component and various [***] (the “SiN Uni Knee”). 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 1.2 Development of SiN Components. Amedica shall be responsible for the
manufacture of all SiN components listed above and shall be obligated as any manufacturer of record with respect to such components. 
 1.3
Development of the Non-SiN Components. [***] shall be responsible for the manufacture of all non-SiN components listed above and shall be obligated as any manufacturer of record with respect to such components. 

1.4 Access to Technology. Each Party shall be required to contribute certain of its own technology as set out above, including
without limitation [***], as well as [***] products (collectively, the “Technology”) to the joint development projects outlined above. Accordingly, each Party agrees to ensure that all [***] access to and/or utilization of the other
Party’s Technology is made available upon [***] of a Party in order to carry out the activities contemplated by this Agreement. 
 1.5
U.S. Clinical Trial  
 1.5.1 Pre-Market Approval. The Parties acknowledge that the SiN Hip System will require
Pre-Market Approval (a “PMA”) as that term is defined by the U.S. Food & Drug Administration (the “FDA”). The Parties represent to each other [***] the duties and responsibilities contained in this Section 1.5 in
order to secure a PMA for the SiN Hip System. 
 1.5.2 Joint Ownership of SiN Hip System PMA. Once the PMA for the SiN Hip
System is granted by the FDA, Amedica and OSI shall [***] such PMA and will with respect to the PMA. Notwithstanding the foregoing, OSI shall [***] the SiN technology contained in the SiN Hip and Knee Systems made the subject of the PMA and [***]
such technology in connection with [***] of the SiN Hip System. 
 1.5.3 Reimbursement. The Parties shall work together to
ensure that products made the subject of the clinical trial will be reimbursable by applicable third party payors, including without limitation the Center for Medicare and Medicaid Services (“CMS”), and shall undertake all necessary
actions to obtain such reimbursement. 
 1.5.4 Clinical Trial Protocol. OSI agrees to draft and be bound by a clinical trial
protocol which protocol shall set forth all particulars of the trial, including without limitation the duties required of OSI in connection with the clinical trial (the “Protocol”). OSI shall ensure that the Protocol is consistent and
complies with all applicable FDA rules and regulations for trials such as the one contemplated herein and shall abide by the Protocol without deviation when conducting the trial. The Protocol shall be reviewed and approved by Amedica. 

1.5.5 Clinical Trial Costs. OSI shall be responsible for [***] associated with the clinical trial contemplated by this
Section 1.5 and shall enter into all necessary agreements with third parties, including without limitation investigators, monitors, and clinical sites, as needed to carry out the Protocol requirements. . 

1.6 Ex-US Markets. The Parties agree to work closely together in an effort to market and sell certain Products [***]. With
respect to those components which are CE Marked or otherwise cleared for sale in other jurisdictions as of the Effective Date, or which will be so cleared during the term of this Agreement, the Parties agree to [***]for marketing and sale of the
Products, and to take all necessary steps [***] as soon as practicable. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE II 

OBLIGATIONS OF AMEDICA 
 2.
Obligations of Amedica. Amedica acknowledges and agrees that it shall be responsible as follows in connection with its participation in the joint development of the Products: 

2.1 Amedica shall undertake all manufacturing and related quality obligations in accordance with Good Manufacturing Practices and all related
laws, regulations and guidelines as they apply to manufacturers of implantable medical devices. 
 2.2 Amedica shall undertake and be
responsible for all testing on the SiN components and shall make all test results and related data available to OSI upon request. Additionally, Amedica shall be responsible for compiling and/or interpreting all such data in connection with all
regulatory approvals and related processes. 
 2.3 In the event that [***], as that term is defined by any regulatory or licensing body, is
required for any of the Products described in the Distribution Agreement, Amedica shall [***] in the costs of same. 
 2.4 Amedica shall
produce all necessary SiN components for the clinical trial contemplated hereunder. 
 ARTICLE III 

OBLIGATIONS OF OSI 
 3. Obligations
of OSI. OSI acknowledges and agrees that it shall be responsible as follows in connection with its participation in the joint development of the Products: 

3.1 OSI shall undertake all manufacturing and related quality obligations in accordance with Good Manufacturing Practices and all related
laws, regulations and guidelines as they apply to manufacturers of implantable medical devices. 
 3.2 OSI shall provide all non-SiN
implants and instrumentation required for development and use of the Products. 
 3.3 OSI shall provide all required marketing support for
the marketing and sale of the Products during the License Period, as that term is defined below. 
 3.4 In the event that [***], as that
term is defined by any regulatory or licensing body, is required for any of the Products, such [***] shall be [***] by OSI. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE IV 

CONFIDENTIAL INFORMATION 
 4.
Confidential Information. 
 4.1 In order to fulfill their respective obligations pursuant to this Agreement, Amedica and
OSI will necessarily have access to certain information relating to the each other which information is considered by the Party who owns it to be confidential, proprietary or otherwise not for public dissemination. Such information shall include but
not be limited to organizational specifics of a Party, business and operating plans, manufacturing processes and protocols, research and development activities, sales activities, technical information, trade secrets, customer lists, and names of
suppliers and other vendors (collectively, the “Confidential Information”). Each Party will hold all Confidential Information of the other Party as a fiduciary, in strict confidence and trust for the other Party’s benefit, and will
not, except as expressly permitted by the Party to whom such Confidential Information belongs, at any time during the term of this Agreement or thereafter, disclose any Confidential Information, in whole or in part, to any third party, or use same
for its own benefit or for the benefit of any third party without the prior written consent of a duly authorized officer of the Party to whom the Confidential Information belongs. 

4.2 Confidential Information does not include: 

4.2.1 any idea or information that is already in the public domain or hereafter falls within the public domain without fault on
the part of the Party to whom the Confidential Information is disclosed; 
 4.2.2 any idea or information for which the right
to use such information has been validly obtained through license or disclosure from any third party with the right to give such license or make such disclosure; 

4.2.3 any idea or information that was in the possession of either Party prior to the Effective Date; or 

4.2.4 any information developed independently by a Party without the use of the other Party’s Confidential Information
disclosed hereunder or otherwise. 
 4.3 Upon request of either Party or upon expiration or termination of this Agreement, any Party so
requested will promptly return all Confidential Information to the requesting Party to the extent held by a Party in written, graphic, or other tangible form, and all copies, summaries, notes and other write-ups made by that Party. The provisions of
this Article IV will survive expiration or termination of this Agreement and remain in effect as long as the Confidential Information remains confidential information of either Party. 

4.4 Remedy for Breach. The Parties acknowledges that any failure by either of them to comply with the provisions of this Article
IV will result in irreparable and continuing injury to the Party to whom the Confidential Information belongs for which there will be no adequate remedy at law; and, in the event that either Party fails to comply with the terms and conditions
contained in this Article IV, the Party whose Confidential Information has been compromised shall be entitled to seek, in addition to such other relief as may be proper, to all types of equitable relief (including, but not limited to, the issuance
of any injunction or temporary restraining order) as may be necessary to cause the non-compliant Party to comply with this Article IV, and both Parties waive the securing or posting of any bond in connection with such remedy. If any action at law or
in equity is brought to enforce or interpret the provisions of this Confidentiality Agreement, the prevailing Party in such action shall be entitled to reasonable attorneys’ fees, as well as all other costs and expenses incurred in securing
relief hereunder. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE V 

LICENSING, DISTRIBUTION, AND PRICING 

5.1 Licensing Rights of SiN Components. OSI shall have a non-exclusive worldwide license to all SiN components identified herein
and used in OSI hip and knee products as contemplated herein, which license shall last in perpetuity (the “License”). Amedica agrees that for a period of two (2) years, which time period shall begin to run for each device upon its
commercialization in the US market (the “Exclusive License Period”), Amedica shall not license or otherwise market the SiN technology to any third party for use in hip and/or knee systems or components. Thereafter, Amedica may, in its sole
discretion use the SiN technology for other hip and knee products in collaboration with any third party of Amedica’s choosing. The Parties agree that all OSI manufactured components remain the sole and exclusive property of OSI and Amedica has
no license or other right to market or sell such components other than as contemplated in this Agreement. 
 5.2 Distribution.
The Parties [***] and use their best efforts to market, distribute, and sell the Products in markets both in and outside of the United States. The Parties shall provide [***] to each other in the undertaking of each Party’s distribution efforts
and OSI expressly agrees [***]. 
 5.3 CE Mark. Amedica shall continue its application for a CE Mark for the femoral component
and shall own such CE Mark in perpetuity once granted. OSI shall be entitled to use the CE Mark for as long as OSI markets, distributes, and sells the Products. OSI shall be responsible for the CE Mark approval for the complete hip system that will
be utilized in concert with Amedica’s CE Marked femoral components. 
 5.4 Forecasts. OSI shall provide to Amedica [***]
forecast which forecast shall be updated on a [***]. 
 5.5 Pricing and Revenue Share. The Parties shall mutually agree on
pricing for the Products, which pricing shall depend upon all reasonable and customary factors including without limitation geographical area, availability of discounts and/or rebates, etc. To the extent that Products are sold as part of a total hip
or knee system, individual component pricing shall be agreed upon between the Parties prior to any sale to any third Party. All such prices shall be committed to writing. The Parties expressly acknowledge and agreed that sharing of revenue under
this Section 5.5 only applies to SiN components included in any OSI total hip or knee systems, or any SiN components identified herein and sold separately. The Parties shall share equally the net margin amount for each Product, which amount
shall equal the actual sales price of each product less (i) discounts and/or rebates; (ii) usual and customary manufacturing costs of all components; (iii) commissions paid to sales personnel; and (iv) delivery costs. Either
Party will have the right to auditall cost calculations upon reasonable notice in writing to the other Party, however in no event shall such right to audit be exercised more than once per calendar year. In the event that an audit evidences that such
costs have been figured incorrectly and to the detriment of the Party requesting the audit, all monies due and owing the Party requesting the audit shall be made within thirty (30) days of the Parties’ receipt of the written audit report,
unless the report findings are disputed by either Party. In the event that such an audit shows a variance of more than ten percent (10%), the Party against whom such variance is levied shall bear all reasonable costs of the audit. 

ARTICLE VI 

REPRESENTATIONS AND WARRANTIES 

6.1 Ability to Contract. The Parties hereby represent and warrant that neither of them is prohibited from entering into this
Agreement, marketing or selling the Products, or otherwise conducting 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
business as contemplated hereunder, whether due to any contract, commitment or obligation binding a Party hereto. Furthermore, the Parties represent and warrant to each other as follows:
(i) that the execution, delivery and performance of this Agreement and compliance with its terms will not result in a breach of any agreement to which either Party, or any of either Party’s employees or agents, is a party; (ii) each
Party is fully authorized to enter into this Agreement and duly authorized and organized to conduct business as provided herein; (iii) each Party’s entrance into and performance under this Agreement does not violate or breach its charter
or corporate bylaws or any agreement or contract to which it is a party; (iv) neither Party has any legal obligations which would prevent this Agreement from being fully implemented in accordance with its terms and, furthermore, each Party has,
and shall maintain, all required licenses and permits; and (v) each Party has been formed and operated and will continue to operate in compliance with all applicable federal and state laws, including, without limitation, those regulations
promulgated by the Food & Drug Administration, as well as all regulatory bodies located in jurisdictions where the Parties shall do business with respect to the Products. 

6.2 The Parties acknowledge and agree as follows: 

6.2.1 The Parties are entering into this Agreement and any other related documents or transactions, with the intent of
conducting their relationship in full compliance with all applicable laws including, but not limited to, federal, state and local Anti-Kickback statutes, Stark laws and any other applicable fraud and abuse provisions. Notwithstanding any
unanticipated effect of any of the provisions herein, neither party will intentionally conduct itself under the terms of this Agreement or any related documents or transactions, in a manner which violates any such laws. 

6.2.2 The Parties agree that they will comply with all applicable legal requirements relating to any protected health
information (“PHI”), including, without limitation, the Health Information Portability and Accountability Act of 1996 and its rules and regulations, as amended (“HIPAA”) to the extent it is applicable. 

6.2.3 The Parties represent and warrant that they: (i) will not violate or cause the other Party to violate any provision
of United States law; (ii) shall comply at all times with all worldwide applicable laws, including, without limitation, those related to medical devices, advertising, warranties, environmental concerns, national security, registration of
commercial representatives, and employment; (iii) shall comply with the United States Food and Drug Administration’s current Good Manufacturing Practices (or any successor quality system regulations), to the extent that the same apply to
the Parties’ respective obligations under this Agreement, including, but not limited to, the following: (A) preparing and maintaining records sufficient to enable identification of the geographic location and contact information of all
customers for all Products; and (B) establishing and maintaining a system for receiving, documenting, and, to the extent such Party holds the FDA clearance for the Products, investigating complaints about the Products. 

ARTICLE VII 
 TERM AND
TERMINATION 
 7.1 Term. The term of this Agreement shall begin upon the Effective Date and expire five (5) years
thereafter (the “Term”). The Parties shall be free to mutually agree to any extension or renewal of this Agreement to the extent that same is memorialized in writing and signed by both Parties. Notwithstanding the foregoing, expiration of
this Agreement pursuant to this Section 7.1 shall not affect the License granted in Article V hereof or the License Period, also indentified in Article V hereof. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 7.2 Termination. This Agreement may be terminated as follows: 

7.2.1 by either Party in the event that the other Party breaches this Agreement and fails to cure such breach within thirty
(30) days of its receipt of written notice from the non-breaching party adequately specifying the details of such breach; 

7.2.2 either Party, by written notice to the other, may terminate this Agreement immediately if the other Party:
(i) ceases or suspends its business; (ii) becomes subject to any bankruptcy or insolvency proceeding under federal or state law; (iii) becomes insolvent or becomes subject to direct control by a trustee, receiver or similar authority;
(iv) has wound up or liquidated its business voluntarily or otherwise; or (v) is debarred, suspended, excluded, or otherwise sanctioned with respect to any federal or state health care reimbursement program or sanctioned in connection with
any of the applicable federal or state health care fraud and abuse laws; or (vi) fails to exercise its best development and/or commercialization efforts concerning this agreement; or 

7.2.3 immediately by either Party if the other Party intentionally engages in wrongful acts which materially impair the
goodwill or business of the Party who is terminating the Agreement hereunder or cause material damage to such Party’s property, goodwill, or business. 

7.3 Surviving Provisions. The Parties expressly agree that the provisions contained in Article V regarding the License, License
Period, and Revenue Sharing relative to the Products shall survive the expiration and/or earlier termination of this Agreement unless otherwise agreed by the Parties or in the event of a breach of this Agreement by either Party. 

ARTICLE VIII 

INDEMNIFICATION 
 8.1
By Amedica. To the extent not otherwise covered by insurance, Amedica shall defend, indemnify and hold harmless OSI from and against any liabilities, losses, damages, costs and expenses (including reasonable attorney fees and other
costs and expenses) arising out of any claim or action brought against the OSI alleging that any of the Products manufactured by Amedica and made the subject of this Agreement infringe any United States patent, copyright, trademark or trade secret
under United States law, provided that, OSI promptly notifies Amedica in writing of such claim, if it becomes aware of such claim, and allows Amedica to control, and reasonably cooperates with Amedica in, the defense of any such claim or action and
any settlement negotiations related thereto. Notwithstanding the above, OSI shall have no liability for any settlement or compromise made without its express written consent, which consent shall not be unreasonably withheld. In the event of a
claimed infringement, Amedica reserves the right to do any of the following: replace the Product with a non-infringing product or a product of equivalent functionality; modify the Product to make it non-infringing; procure for the Parties hereto the
right to continue using said Product; or remove the Product from its inclusion in the activities contemplated hereunder. The foregoing constitutes Amedica’s entire liability in the event of any claim of intellectual property infringement. 

8.2 By OSI. To the extent not otherwise covered by insurance, OSI shall defend, indemnify and hold harmless Amedica from and
against any liabilities, losses, damages, costs and expenses (including reasonable attorney fees and other costs and expenses) arising out of any claim or action brought against the Amedica alleging that any of the Products manufactured by OSI and
made the subject of this Agreement infringe any United States patent, copyright, trademark or trade secret under United States law, provided that, Amedica promptly notifies Amedica in writing of such claim, if it becomes aware of such claim, and
allows OSI to control, and reasonably cooperates with OSI in, the defense of any such claim or action and any settlement negotiations related thereto. Notwithstanding the above, Amedica shall have no liability for any settlement or compromise made
without its express written consent, which consent shall not be 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
unreasonably withheld. In the event of a claimed infringement, OSI reserves the right to do any of the following: replace the Product with a non-infringing product or a product of equivalent
functionality; modify the Product to make it non-infringing; procure for the Parties hereto the right to continue using said Product; or remove the Product from its inclusion in the activities contemplated hereunder. The foregoing constitutes
OSI’S entire liability in the event of any claim of intellectual property infringement. 
 8.3 Indemnification for Product
Liability. The Parties each agree that in the event of any suit, claim, or action brought against a Party alleging product liability, the Party whose product or product component is alleged to have caused the liability, loss, damage, costs,
or expense shall indemnify, defend, and hold harmless the other Party, provided that the Party seeking indemnification gives prompt written notice of such suit, claim, or action to the other Party. Notwithstanding the foregoing, failure to provide
notice as set out in this Section 8.3 shall not serve to relieve the indemnifying Party of their obligations hereunder unless such failure to give notice substantially prejudiced the indemnifying Party with respect to its ability to defend
against such suit, claim, or action. 
 ARTICLE IX 

MISCELLANEOUS PROVISIONS 
 9.
Miscellaneous Provisions. 
 9.1 Entire Agreement; Modification and Amendment. This Agreement, along with any
attachments, or exhibits hereto, contains the entire agreement between the Parties with respect to the subject matter hereof and it expressly supersedes any and all other agreements, whether written or oral. No waiver, alteration or modification of
any of the terms and/or conditions contained in this Agreement will be binding unless in writing and signed by authorized representatives of both Parties. 

9.2 Notice. Any notice or communication required or permitted to be given under this Agreement shall be in writing and shall be served
on the Parties at the address of the recipient Party provided above or to such other address as any Party may by written notice designate pursuant to this Section 9.2. Any notice or communication required, permitted or desired to be given by
any provision of this Agreement shall be sent either (i) by prepaid certified or registered mail, return receipt requested, in which case notice shall be deemed received three business days after deposit, postage prepaid in the United States
Mail; (ii) by facsimile with appropriate electronic confirmation, in which case notice shall be deemed received as of the date and time shown on such confirmation; or (iii) by nationally recognized overnight courier with signature
confirmation, in which case notice shall be deemed upon actual receipt. 
 9.3 Assignment. This Agreement is non-transferable
except as permitted in this paragraph. Either Party to this Agreement may assign its interest under this Agreement to any entity controlling, controlled by or under common control with such Party or an entity which is succeeding to the entire
business of Company; provided, however, that either Party must assign its rights and obligations under this Agreement to any purchaser of all or substantially all of the assets of said Party, in which case the purchaser shall remain liable for all
of such Party’s obligations hereunder. 
 9.4 Relationship of the Parties. Nothing in this Agreement is intended
to create an exclusive business relationship between the Parties except as set out herein, nor will this Agreement be deemed or construed to constitute or create between the Parties a partnership, joint venture, agency, or other legal business
entity.  

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 9.5 Governing Law. This Agreement shall be governed by the laws of Delaware,
without regard to conflicts of law principles. Venue for any dispute arising hereunder shall be as follows: (i) for suits, claims, and/or actions brought by OSI, venue shall be in the federal and/or state courts of competent jurisdiction
located in Salt Lake City, Salt Lake County, Utah; and (ii) for suits, claims, and/or actions brought by Amedica, venue shall be in the federal and/or state courts of competent jurisdiction located in Bristol County, Massachusetts. 

9.6 Arbitration. If the Parties are unable to resolve any dispute arising out of or relating to the performance of this
Agreement, such dispute shall be submitted to final and binding arbitration in accordance with the rules for commercial arbitration of the American Arbitration Association (the “AAA”) then in effect, before a three party panel of the AAA.
Such arbitration proceedings shall take place in Boston, Massachusetts if initiated by Amedica and in Salt Lake City, Utah if initiated by OSI. Notwithstanding any rules of the AAA, the Parties shall be entitled to discovery in accordance with the
Federal Rules of Civil Procedure. One member of the panel shall be selected by Amedica, one member of the panel shall be selected by OSI, and Amedica and OSI shall agree upon the third member from a proposed list of panelists submitted by the AAA,
or, if they cannot agree on the third member, either Party may request the two selected panel members to appoint the third member, which appointment shall be binding upon the Parties. The arbitrators shall issue a reasoned written decision together
with their award. Judgment on any arbitration award may be entered in any court of competent jurisdiction. 
 9.7 Validity and Change
in Law. Should any provision of this Agreement be rendered unlawful or invalid because of any existing or subsequently enacted law or by a decree or order of a court of last resort, the remaining provisions will continue in full force and
effect. The Parties agree to negotiate in good faith to reform any provision rendered unlawful or invalid and to preserve, as nearly as possible, the original intent of the Parties with respect to such provision. 

9.8 Force Majeure. If during the term of this Agreement an event of force majeure should prevent either Party from fulfilling
its obligations, the Party so affected shall be excused from any liability for non-performance during the period of such force majeure; provided however, if such force majeure continues for more than [***] then either Party may terminate this
Agreement. For purposes of this Agreement force majeure includes but is not limited to acts of God, war, acts of terrorism, civil unrest, natural disasters, and any other unforeseen and/or uncontrollable event which affects either Party’s
ability to perform hereunder. 
 9.9 Waiver. Failure by one Party to notify the other Party of a breach of any provision of
this Agreement shall not constitute a waiver of any continuing breach. Failure of one Party to enforce any of its rights under this Agreement shall not constitute a waiver of those rights. The waiver by either Party of a breach or violation of this
Agreement, which waiver must be in writing and signed by the Party against whom the waiver is sought, shall not operate as, or be construed to be, a waiver of any subsequent breach of the same or any other provision hereof. 

9.10 Counterparts. This Agreement shall be executed in multiple counterparts, each considered an original for any and all
purposes and all of which together shall constitute one and the same document. 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.
Both Parties represent and warrant that the individuals signing on behalf of each Party have the requisite authority to bind their respective Party to each and every of the terms and conditions contained in this Agreement. 

 

					
	AMEDICA CORPORATION	 		 	ORTHOPAEDIC SYNERGY, INC.
			
	 /s/ Ben Shappley
	 		 	 /s/ Richard D. Nikolaev

	Ben Shappley, Chief Executive Officer	 		 	Richard D. Nikolaev, Chief Executive Officer

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]